← ANALYST RATINGS · TIPRANKS
Alkermes (ALKS): analyst forecast and price target
Analyst consensus
Moderate Buy9 Buy3 Hold1 Sell
Ratings of 13 analysts in the last 3 months12-month forecast
Based on 13 price targets given in the last 3 months, the average target is $59.08, the highest $83.00, the lowest $38.00. The average is +43.3% from the last price of $41.22.
Analyst ratings 24
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $44.00 → $43.00−2.3% | Buy | +4.3% | Upgrade | 15.10.26on TipRanks 12:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $39.00 → $38.00−2.6% | Hold | −7.8% | Reiterated | 15.10.26on TipRanks 12:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $41.00 → $40.00−2.4% | Hold | −3.0% | Reiterated | 15.10.26on TipRanks 12:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $42.00 → $41.00−2.4% | Hold | −0.5% | Reiterated | 15.10.26on TipRanks 12:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $42.00 → $41.00−2.4% | Hold | −0.5% | Reiterated | 15.10.26on TipRanks 12:05 | — | |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $48.00 → $44.00−8.3% | Buy | +6.7% | Upgrade | 14.10.26on TipRanks 06:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $43.00 → $39.00−9.3% | Hold | −5.4% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $44.00 → $41.00−6.8% | Hold | −0.5% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $44.00 → $40.00−9.1% | Hold | −3.0% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $46.00 → $42.00−8.7% | Hold | +1.9% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $46.00 → $42.00−8.7% | Hold | +1.9% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $38.00 | Sell | −7.8% | Reiterated | 09.10.26on TipRanks 08:55 | +0.6%next day −0.8% · 5 days +3.5% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $56.00 | Buy | +35.9% | Reiterated | 08.10.26on TipRanks 21:45 | +0.6%next day −0.8% · 5 days +3.5% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $63.00 | Buy | +52.8% | Reiterated | 05.10.26on TipRanks 06:55 | +1.7%next day −3.1% · 5 days −6.3% | ↗ |
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $50.00 | Hold | +21.3% | Initiated | 24.09.26on TipRanks 07:40 | −3.1%next day −0.4% · 5 days −0.2% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $78.00 → $83.00+6.4% | Buy | +101.4% | Reiterated | 22.09.26on TipRanks 08:55 | −2.0%next day −2.0% · 5 days −4.6% | ↗ |
| Luke Herrmann | Robert W. Baird | $58.00 → $61.00+5.2% | Buy | +48.0% | Reiterated | 22.09.26on TipRanks 07:25 | −2.0%next day −2.0% · 5 days −4.6% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $56.00 | Buy | +35.9% | Reiterated | 22.09.26on TipRanks 07:15 | −2.0%next day −2.0% · 5 days −4.6% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $65.00 | Buy | +57.7% | Reiterated | 22.09.26on TipRanks 06:50 | −2.0%next day −2.0% · 5 days −4.6% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | — | Hold | — | Reiterated | 21.09.26on TipRanks Sep 22 07:35 | +0.3%next day −2.0% · 5 days −8.1% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $38.00 | Sell | −7.8% | Reiterated | 21.09.26on TipRanks Sep 22 06:15 | +0.3%next day −2.0% · 5 days −8.1% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $43.00 | Hold | +4.3% | Reiterated | 21.09.26on TipRanks 12:45 | +0.3%next day −2.0% · 5 days −8.1% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $62.00 | Buy | +50.4% | Reiterated | 21.09.26on TipRanks 10:15 | +0.3%next day −2.0% · 5 days −8.1% | ↗ |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $48.00 | Buy | +16.4% | Upgrade | 21.09.26on TipRanks 09:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $43.00 | Hold | +4.3% | Reiterated | 21.09.26on TipRanks 09:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $44.00 | Hold | +6.7% | Reiterated | 21.09.26on TipRanks 09:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $44.00 | Hold | +6.7% | Reiterated | 21.09.26on TipRanks 09:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $46.00 | Hold | +11.6% | Reiterated | 21.09.26on TipRanks 09:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $45.00 → $46.00+2.2% | Hold | +11.6% | Reiterated | 21.09.26on TipRanks 09:05 | — | |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $65.00 | Buy | +57.7% | Reiterated | 06.08.26on TipRanks 07:01 | −2.3%next day +1.0% · 5 days +1.0% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $65.00 | Buy | +57.7% | Assigned | 29.07.26on TipRanks 07:02 | −2.7%next day +1.8% · 5 days −2.9% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | $57.00 → $58.00+1.8% | Buy | +40.7% | Reiterated | 28.07.26on TipRanks 13:30 | −4.5%next day −2.7% · 5 days −5.8% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $45.00 → $63.00+40.0% | Buy | +52.8% | Reiterated | 25.07.26on TipRanks Jul 27 06:17 | −0.3%next day −4.5% · 5 days −8.6% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $42.00 → $48.00+14.3% | Buy | +16.4% | Reiterated | 06.05.26on TipRanks 06:40 | −4.0%next day +0.5% · 5 days +9.0% | ↗ |
| Marc Goodman★★★★★★★★★★#365 · hits 56% · avg +19.2% | Leerink Partners | — | Hold | — | Reiterated | 31.03.26on TipRanks 13:25 | +14.4%next day −1.6% · 5 days −5.6% | ↗ |
| Pete Stavropoulos★★★★★★★★★★#2065 · hits 45% · avg +16.4% | Cantor Fitzgerald | $43.00 | Buy | +4.3% | Reiterated | 11.03.26on TipRanks Mar 12 08:25 | +0.2%next day +1.1% · 5 days +0.2% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | — | Buy | — | Reiterated | 26.02.26on TipRanks Feb 27 02:35 | −0.4%next day −1.6% · 5 days −6.6% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $45.00 | Buy | +9.2% | Initiated | 23.02.26on TipRanks Feb 24 03:35 | +1.9%next day +3.0% · 5 days −6.6% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $55.00 → $45.00−18.2% | Buy | +9.2% | Reiterated | 13.11.25on TipRanks 04:15 | +0.4%next day −6.3% · 5 days −6.2% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Buy | — | Reiterated | 12.11.25on TipRanks 12:55 | −7.2%next day +0.4% · 5 days −5.6% | ↗ |
| Unknown Analyst | Roth MKM | $50.00 | Buy | +21.3% | Initiated | 10.11.25on TipRanks Nov 11 12:10 | −2.3%next day +3.3% · 5 days −7.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Alkermes
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $59.08 at a price of $40.52 (+45.8%); now: $59.08 at $41.22 (+43.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 1 | 0 | 0 | 3 | 3 |
| Buy | 21 | 31 | 40 | 28 | 21 | 8 |
| Hold | 4 | 4 | 8 | 6 | 8 | 3 |
| Sell | 0 | 1 | 3 | 3 | 3 | 2 |
Earnings and sales forecast
Next report: 28.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.08 (from $-0.15 to $0.00). Last quarter: $0.00.
Sales
Next quarter’s sales estimate — $464M (from $445M to $482M). Last quarter: $496M.
Best top-analyst consensus in the sector · Healthcare
About Alkermes
- CEO: Blair Jackson
- Employees: 2,050
- Connaught House, Dublin, DU, D04 C5Y6, IE
- www.alkermes.com
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Data from the stock’s TipRanks forecast page, read 5 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗